Lincoln Pharmaceuticals Ltd
NSE:LINCOLN

Watchlist Manager
Lincoln Pharmaceuticals Ltd Logo
Lincoln Pharmaceuticals Ltd
NSE:LINCOLN
Watchlist
Price: 553.1 INR -0.3%
Market Cap: 11.1B INR
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one LINCOLN stock under the Base Case scenario is 712.9 INR. Compared to the current market price of 553.1 INR, Lincoln Pharmaceuticals Ltd is Undervalued by 22%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

LINCOLN Relative Value
Base Case
712.9 INR
Undervaluation 22%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

1.9
P/S
P/S
Price to Sales
1.9
vs History
26
vs Industry
50
Median 3Y
1.8
Median 5Y
1.5
Industry
2.4
Forward
1.7
More Details
12.4
P/E
P/E
Price to Earnings
12.4
vs History
25
vs Industry
32
Median 3Y
11.7
Median 5Y
9.9
Industry
20.2
Forward
10.5
More Details
17.1
P/OCF
P/OCF
Price to OCF
17.1
vs History
33
vs Industry
22
Median 3Y
17.9
Median 5Y
11.6
Industry
15.1
More Details
45
P/FCFE
P/FCFE
Price to FCFE
45
vs History
17
vs Industry
10
Median 3Y
25.3
Median 5Y
19.1
Industry
22.3
More Details
1.7
P/B
P/B
Price to Book Value
1.7
vs History
33
vs Industry
38
Median 3Y
1.7
Median 5Y
1.6
Industry
2
More Details
1.5
EV/S
EV/S
Enterprise Value to Sales
1.5
vs History
26
vs Industry
54
Median 3Y
1.4
Median 5Y
1.2
Industry
2.5
Forward
1.4
More Details
2.9
EV/GP
EV/GP
Enterprise Value to Gross Profit
2.9
vs History
26
vs Industry
52
Median 3Y
2.7
Median 5Y
2.3
Industry
4.9
More Details
9.8
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
9.8
vs History
22
vs Industry
32
Median 3Y
8.6
Median 5Y
6.5
Industry
12.3
More Details
11.2
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
11.2
vs History
22
vs Industry
34
Median 3Y
9.6
Median 5Y
7
Industry
15.3
Forward
8.6
More Details
14.1
EV/OCF
EV/OCF
Enterprise Value to OCF
14.1
vs History
34
vs Industry
24
Median 3Y
15.5
Median 5Y
10.1
Industry
13.6
More Details
35.9
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
35.9
vs History
17
vs Industry
10
Median 3Y
18
Median 5Y
14.5
Industry
17.5
More Details
1.9
EV/IC
EV/IC
Enterprise Value to IC
1.9
vs History
33
vs Industry
34
Median 3Y
1.8
Median 5Y
1.6
Industry
1.7
More Details

Multiples Across Competitors

LINCOLN Competitors Multiples
Lincoln Pharmaceuticals Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
IN
Lincoln Pharmaceuticals Ltd
NSE:LINCOLN
11.1B INR 1.9 12.4 9.8 11.2
US
Eli Lilly and Co
NYSE:LLY
798.4B USD 17.7 75.4 43.8 48.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
392.4B USD 4.4 27.9 13.1 17.1
DK
Novo Nordisk A/S
CSE:NOVO B
2.4T DKK 8.3 23.9 15.7 17.9
CH
Roche Holding AG
SIX:ROG
244B CHF 4.2 21.2 11.8 14
US
Merck & Co Inc
NYSE:MRK
239.9B USD 3.7 14 9.4 11.1
UK
AstraZeneca PLC
LSE:AZN
183.1B GBP 4.4 33.8 127.4 194.5
CH
Novartis AG
SIX:NOVN
202B CHF 4.4 19.2 11.6 14.9
IE
Endo International PLC
LSE:0Y5F
166.1B USD 71.6 -56.8 265.3 665.3
US
Pfizer Inc
NYSE:PFE
148.4B USD 2.3 18.5 8.8 12.5
P/E Multiple
Earnings Growth PEG
IN
Lincoln Pharmaceuticals Ltd
NSE:LINCOLN
Average P/E: 27.4
12.4
16%
0.8
US
Eli Lilly and Co
NYSE:LLY
75.4
48%
1.6
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
27.9
26%
1.1
DK
Novo Nordisk A/S
CSE:NOVO B
23.9
19%
1.3
CH
Roche Holding AG
SIX:ROG
21.2
16%
1.3
US
Merck & Co Inc
NYSE:MRK
14
17%
0.8
UK
AstraZeneca PLC
LSE:AZN
33.8
36%
0.9
CH
Novartis AG
SIX:NOVN
19.2
16%
1.2
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -56.8 N/A N/A
US
Pfizer Inc
NYSE:PFE
18.5
29%
0.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
IN
Lincoln Pharmaceuticals Ltd
NSE:LINCOLN
Average EV/EBITDA: 396.6
9.8
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
43.8
29%
1.5
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
13.1
7%
1.9
DK
Novo Nordisk A/S
CSE:NOVO B
15.7
11%
1.4
CH
Roche Holding AG
SIX:ROG
11.8
7%
1.7
US
Merck & Co Inc
NYSE:MRK
9.4
11%
0.9
UK
AstraZeneca PLC
LSE:AZN
127.4
8%
15.9
CH
Novartis AG
SIX:NOVN
11.6
4%
2.9
IE
E
Endo International PLC
LSE:0Y5F
265.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
8.8
2%
4.4
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
IN
Lincoln Pharmaceuticals Ltd
NSE:LINCOLN
Average EV/EBIT: 1 700.8
11.2
19%
0.6
US
Eli Lilly and Co
NYSE:LLY
48.3
31%
1.6
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
17.1
11%
1.6
DK
Novo Nordisk A/S
CSE:NOVO B
17.9
16%
1.1
CH
Roche Holding AG
SIX:ROG
14
9%
1.6
US
Merck & Co Inc
NYSE:MRK
11.1
12%
0.9
UK
AstraZeneca PLC
LSE:AZN
194.5
19%
10.2
CH
Novartis AG
SIX:NOVN
14.9
9%
1.7
IE
E
Endo International PLC
LSE:0Y5F
665.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
12.5
10%
1.2

See Also

Summary
LINCOLN intrinsic value, competitors valuation, and company profile.
DCF Valuation
LINCOLN stock valuation using Discount Cash Flow valuation method.
Relative Valuation
LINCOLN stock valuation using valuation multiples.
Wall Street Estimates
LINCOLN price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
LINCOLN stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 240,000+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.